Literature DB >> 3598194

An improved method for the generation of human lymphokine activated killer cells.

J R Yannelli, G B Thurman, S G Dickerson, A Mrowca, E Sharp, R K Oldham.   

Abstract

In an effort to make interleukin-2/lymphokine-activated killer cell (IL-2/LAK) therapy safer for cancer patients, we examined the efficacy of using Fenwal PL732 bags as tissue culture flasks. These bags can be sterilly connected using tubing kits thus reducing the risk of contamination to the cells. Peripheral blood mononuclear cells were obtained from normal donors or cancer patients undergoing IL-2/LAK cell therapy. Following Ficoll-Hypaque purification, these cells were incubated in the presence of IL-2 in either PL732 plastic bags or standard tissue culture flasks. Our results showed that LAK cells could be generated from either normal donors or cancer patients in the bags as well as in the flasks. Comparisons were made of the LAK cell populations obtained from the two sources and showed that each was similar in terms of morphology as determined by Wright stain differentials. The populations of cells were also similar in regard to cell surface phenotype as determined by flow cytometric analysis. In addition, recoveries from either tissue culture vessel as well as cell viability of the LAK cells were comparable. Finally, the LAK cells obtained from both sources were assessed for cytolytic activity against the tumor cell lines K562 and Daudi. These results showed that the cytolytic activity of the LAK cells against these target cells was the same whether the cells were obtained from the flasks or the bags.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598194     DOI: 10.1016/0022-1759(87)90182-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  To the editor.

Authors:  J R Yannelli; A M Bastin; M Jadus
Journal:  Cytotechnology       Date:  1988-02       Impact factor: 2.058

2.  Simple manual method for making cell smears of leukapheresis and cell culture products: application to human LAK cell laboratories.

Authors:  C A Heiny; J R Yannelli
Journal:  Cytotechnology       Date:  1988-07       Impact factor: 2.058

3.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.

Authors:  C Fortis; E Ferrero; M Biffi; S Heltai; C Besana; E Bucci; M Tresoldi; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Simplified long term large scale production of highly active human LAK cells for therapy.

Authors:  P Wersäll; G Masucci; P Pihlstedt; H Wigzell; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.